Differential staphylococcal protein A-induced enhancement of natural killer cell activity of lymphocytes from HIV-seropositive individuals.
A decrease in Natural Killer (NK) cell activity is a common feature of the immune dysfunction found in patients with HIV-induced acquired immune deficiency syndrome (AIDS). We and others have shown earlier that staphylococcal protein A (SpA) preparations enhance NK cell activity against tumor targets. The present study was aimed at exploring whether the decreased NK activity of lymphocytes from HIV seropositive subjects could be modulated or restored in vitro by SpA. Two types of HIV-seropositive subjects were studied: hemophiliac and non-hemophiliac; matched controls were chosen among hospital staff and HIV-seronegative hemophiliac volunteers. In vitro proliferation and interleukin-2(IL-2)/interferon gamma (IFN gamma) release in response to mitogens were also studied. NK cell responses of peripheral blood lymphocytes (PBL) of HIV-seropositives were lower than those of seronegatives. However, exposure of PBL from HIV-seropositive individuals to SpA boosted their NK cell responses against NK-resistant target cells of tumor origin. The decrease in NK activity could not be attributed to the low number of NK cells, since no significant difference in NK cell number was observed between HIV-seropositive individuals and controls. Mitogen-induced blastogenic responses were present in all four groups, as was the mitogen-induced IFN gamma release. We conclude that impaired NK activity and its boosting against NK-resistant targets after SpA induction is an important characteristic of lymphocytes of HIV-seropositive individuals regardless of the disease state and that this NK defect may not be irreversible.(ABSTRACT TRUNCATED AT 250 WORDS)
Kasparian
S
S
Laboratory of Immunovirology, University of Montreal, Québec, Canada.
Stefanescu
I
I
Rivard
G E
GE
Menezes
J
J
D000328:Adult; D016516:CD4-CD8 Ratio; D006679:HIV Seropositivity / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006467:Hemophilia A / Q000150:complications; D006801:Humans; D007167:Immunotherapy; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000096:biosynthesis; D007694:Killer Cells, Natural / Q000276:immunology*; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008297:Male; D013205:Staphylococcal Protein A / Q000276:immunology*
D007376:Interleukin-2; D013205:Staphylococcal Protein A